Latest News

LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360® Peripheral Orbital Atherectomy System (OAS) 08/10/17
OAS utilization resulted in high Freedom from Major Amputation at one year across all Rutherford Classes (RC 2-3, 100%; RC 4-5, 95.8%; and RC 6, 91.2%) OAS prior to DCB therapy resulted in high Freedom from MAE at one year (95.2%) with no major amputations A new sub-analysis from the landmark LIBERTY 360° study, sponsored by Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), was presented today as part of a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago . The LIBERTY 360° study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in patients with symptomatic lower extremity peripheral artery disease (PAD). Physicians were able to use any FDA-approved device, including CSI’s Diamondback 360® Peripheral OAS, which was the most frequently used atherectomy device in the study. The sub-analysis, highlighting 12-month Freedom from Major Adverse Events and Major Amputation, supports...
LIBERTY 360° Study 12-Month Data Demonstrate Lasting Benefits Following Endovascular Intervention in Patients with Critical Limb Ischemia (CLI) 08/10/17
Landmark 1,200 patient study 12-month clinical data shared at Amputation Prevention Symposium Patients across all Rutherford Classes show high Freedom from Major Amputation and Major Adverse Events (MAE) CLI patients show improvement in Rutherford Classification (RC), Wound Healing and Quality of Life Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today released one-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago . The LIBERTY 360° study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in patients with peripheral artery disease (PAD). With over 1,200 patients enrolled at 51 sites across the United States, it is among the first PAD studies to investigate patients across the spectrum of symptomatic PAD (RC 2-6). As an “all comers” study, LIBERTY 360°’s novel trial design included any endovascular device FDA-approved for...

Latest SEC Filings

Date Filing Description Download
08/21/17 4 Statement of Changes in Beneficial Ownership
08/21/17 4 Statement of Changes in Beneficial Ownership

Stock Chart